AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9314468 — intervention group
Group type: COMPARATOR
Intervention: Anti-HAV detection in blood donors
Number of subjects: 900
Study 9314468 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of anti-HAV with socioeconomic status in IDUs
Number of subjects: 900
Study 9314468 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of anti-HAV with number of sexual partners in homosexual males
Number of subjects: 900
Study 9314468 — intervention group
Group type: COMPARATOR
Intervention: Comparison of anti-HAV prevalence with general population
Number of subjects: 900
Study 8310852 — intervention group
Group type: EXPERIMENTAL
Intervention: L-sulpiride
Number of subjects: 30
Study 8310852 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 30
Study 3017174 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24
Study 3017174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30868938 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed and humidified CO2 insufflation with HumiGard device, plus hot air warming blanket (H + WB)
Number of subjects: 64
Study 30868938 — intervention group
Group type: COMPARATOR
Intervention: Standard CO2 insufflation, plus hot air warming blanket (WB)
Number of subjects: 64
Study 28403084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin plus vitamin B complex (group GB)
Number of subjects: 128
Study 28403084 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin alone (group G)
Number of subjects: 128
Study 26254845 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose carotenoid-rich juice (2.75 mg carotenoids/30 mL juice)
Number of subjects: 58
Study 26254845 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carotenoid-rich juice (2.75 mg carotenoids/30 mL juice)
Number of subjects: 58
Study 26254845 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 58
Study 23504666 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention (geriatric consultation, continuous rehabilitation, discharge planning)
Number of subjects: 160
Study 23504666 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 160
Study 22364094 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (0.9% NaCl) irrigation with sequential irrigation of 3% H2O2, 5.2% NaOCl and 0.9% NaCl
Number of subjects: 104
Study 22364094 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied to be the other treatment group)
Number of subjects: 104
Study 19095827 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES200/0.5 or 6% HES130/0.4
Number of subjects: 45
Study 19095827 — intervention group
Group type: COMPARATOR
Intervention: 4% human albumin solution
Number of subjects: 45
Study 17005272 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20-40 mg/day) for 8 weeks
Number of subjects: 76
Study 15775796 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 70
Study 15775796 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 70
Study 15775796 — intervention group
Group type: COMPARATOR
Intervention: Losartan vs Atenolol
Number of subjects: 70
Study 12411457 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg/d
Number of subjects: 34
Study 12411457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no canrenone)
Number of subjects: 34
Study 12411457 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors and calcium antagonists (baseline treatment)
Number of subjects: 34
Study 9857348 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (IFN-alpha 2a)
Number of subjects: 469
Study 9857348 — intervention group
Group type: EXPERIMENTAL
Intervention: (re)treatment during long-term follow-up
Number of subjects: 469
Study 9857348 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 469
Study 8580556 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous injection of isosorbide dinitrate (ISDN) at 10 mg/h
Number of subjects: 22
Study 8580556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent injection of isosorbide dinitrate (ISDN) at 10 mg/10 min every 2 hours
Number of subjects: 22
Study 8580556 — intervention group
Group type: COMPARATOR
Intervention: Both continuous and intermittent ISDN
Number of subjects: 22
Study 2213778 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms triiodothyronine (T3) daily
Number of subjects: 18
Study 2213778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 362282 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A therapy (vitamin A palmitate or 13‐cis vitamin A acid)
Number of subjects: 9
Study 31009064 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVA adjustment in randomized trials
Number of subjects: 0
Study 31009064 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear model for outcome given treatment arm and baseline variables
Number of subjects: 0
Study 27897461 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL) group
Number of subjects: 8
Study 27897461 — intervention group
Group type: COMPARATOR
Intervention: Early Loading (EL) group
Number of subjects: 8
Study 26092545 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 50 mg
Number of subjects: 100
Study 26092545 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 100 mg
Number of subjects: 100
Study 26092545 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 200 mg
Number of subjects: 100
Study 26092545 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin with food
Number of subjects: 100
Study 26092545 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 100 mg with omeprazole 40 mg
Number of subjects: 100
Study 26092545 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin in elderly subjects
Number of subjects: 100
Study 26092545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23459487 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg bedaquiline
Number of subjects: 68
Study 23459487 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg bedaquiline
Number of subjects: 68
Study 23459487 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg bedaquiline
Number of subjects: 68
Study 23459487 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg bedaquiline
Number of subjects: 68
Study 21807781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy
Number of subjects: 64
Study 21807781 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 64
Study 21807781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) monotherapy
Number of subjects: 64
Study 19537862 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine dihydrochloride (OCT)
Number of subjects: 18
Study 19537862 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate (CHX)
Number of subjects: 18
Study 19537862 — intervention group
Group type: COMPARATOR
Intervention: Polyvinylpyrrolidone‐iodine complex (PVP‐I)
Number of subjects: 18
Study 16765798 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-site phacotrabeculectomy
Number of subjects: 130
Study 16765798 — intervention group
Group type: COMPARATOR
Intervention: 1-site phacotrabeculectomy
Number of subjects: 130
Study 15001964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained‐release morphine, 1.9 mg/kg every 12 hours
Number of subjects: 15
Study 15001964 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of morphine at 0.04 mg/kg/hour
Number of subjects: 15
Study 15001964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained‐release morphine
Number of subjects: 15
Study 11417848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) for 8 weeks
Number of subjects: 20
Study 11417848 — intervention group
Group type: COMPARATOR
Intervention: Prednisone for 8 weeks (Control)
Number of subjects: 20
Study 9754724 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with pigs
Number of subjects: 662
Study 9754724 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with cats
Number of subjects: 662
Study 9754724 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with dogs
Number of subjects: 662
Study 9754724 — intervention group
Group type: COMPARATOR
Intervention: H. pylori infection
Number of subjects: 662
Study 7918140 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (5-40 mg qd for MRI; 2.5-20 mg qd for CRF)
Number of subjects: 55
Study 7918140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2561750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) administered at one 7500, 15000 or 30000 AXaU vial/day sc for 60 days
Number of subjects: 60
Study 2561750 — intervention group
Group type: COMPARATOR
Intervention: Heparin calcium administered at one or two 12500 IU vials/day sc for 60 days
Number of subjects: 60
Study 1102079 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 24
Study 1102079 — intervention group
Group type: COMPARATOR
Intervention: Alpha feedback
Number of subjects: 24
Study 1102079 — intervention group
Group type: COMPARATOR
Intervention: Joked control group
Number of subjects: 24
Study 1102079 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including EMG, Alpha, and Joked control)
Number of subjects: 24
Study 31837113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40 or 80 mg/day)
Number of subjects: 281
Study 30535188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 90
Study 30535188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27448178 — intervention group
Group type: EXPERIMENTAL
Intervention: Active listening taught as an attitude (6 students)
Number of subjects: 19
Study 27448178 — intervention group
Group type: EXPERIMENTAL
Intervention: Active listening taught as a technique (6 students)
Number of subjects: 19
Study 27448178 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 students)
Number of subjects: 19
Study 24651682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene intervention (29.4 mg of lycopene per day via 11.5 oz of V8 100% vegetable juice for 30 days)
Number of subjects: 40
Study 24651682 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 40
Study 24651682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene intervention
Number of subjects: 40
Study 22187385 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐Hz group
Number of subjects: 55
Study 22187385 — intervention group
Group type: EXPERIMENTAL
Intervention: 26‐Hz group
Number of subjects: 55
Study 22187385 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric group
Number of subjects: 55
Study 22187385 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 22187385 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐Hz and 26‐Hz groups
Number of subjects: 55
Study 22187385 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibrations (8Hz and 26Hz)
Number of subjects: 55
Study 20156067 — intervention group
Group type: COMPARATOR
Intervention: Low-insulin step of the clamp in normal nonobese women
Number of subjects: 8
Study 20156067 — intervention group
Group type: COMPARATOR
Intervention: High-insulin step in normal nonobese women
Number of subjects: 8
Study 20156067 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp studies in obese PCOS women
Number of subjects: 8
Study 18418126 — intervention group
Group type: COMPARATOR
Intervention: Detection of alpha1 integrin in urine using a double-sandwich enzyme-linked immunosorbent assay.
Number of subjects: 29
Study 16011060 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (mud packs and sulfur pool) and exposure to the unique climatic conditions of the Dead Sea
Number of subjects: 28
Study 16011060 — intervention group
Group type: COMPARATOR
Intervention: Climatotherapy (fresh water pool and same climatic conditions)
Number of subjects: 28
Study 12039991 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d sulodexide for 4 months
Number of subjects: 223
Study 12039991 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d sulodexide for 4 months
Number of subjects: 223
Study 12039991 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d sulodexide for 4 months
Number of subjects: 223
Study 12039991 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d sulodexide at T8
Number of subjects: 223
Study 12039991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 10526897 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens (CEE) 0.625 mg daily
Number of subjects: 60
Study 10526897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10526897 — intervention group
Group type: COMPARATOR
Intervention: 50 microg 17beta‐oestradiol transdermally (TTSE) per 24 h
Number of subjects: 60
Study 7723978 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 10
Study 7723978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline injections)
Number of subjects: 10
Study 2183405 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (prothrombin time of 1.3‐1.8 times control)
Number of subjects: 1644
Study 2183405 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day)
Number of subjects: 1644
Study 2183405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1644
Study 7058441 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with various therapeutic agents
Number of subjects: 168
Study 7058441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 31512573 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-led school intervention combining student-driven design and teacher-training component
Number of subjects: 7572
Study 31512573 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 7572
Study 29101128 — intervention group
Group type: EXPERIMENTAL
Intervention: PSORI‐CM01 granules (5.5 g, two times daily)
Number of subjects: 556
Study 29101128 — intervention group
Group type: COMPARATOR
Intervention: Yinxieling tablets (five tablets, three times daily)
Number of subjects: 556
Study 25691622 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin at bedtime
Number of subjects: 290
Study 25691622 — intervention group
Group type: COMPARATOR
Intervention: 100 mg aspirin on awakening
Number of subjects: 290
Study 23759340 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 455
Study 21088598 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI sufentanil (0.3 ng ml⁻¹)
Number of subjects: 100
Study 21088598 — intervention group
Group type: COMPARATOR
Intervention: TCI remifentanil (3 ng ml⁻¹)
Number of subjects: 100
Study 19701826 — intervention group
Group type: EXPERIMENTAL
Intervention: TITANOX stent
Number of subjects: 425
Study 19701826 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 425
Study 17192828 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid volume resuscitation (10% hydroxyethyl starch: 10% Hemohes)
Number of subjects: 0
Study 17192828 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid volume resuscitation (Sterofundin)
Number of subjects: 0
Study 17192828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (Actrapid)
Number of subjects: 0
Study 17192828 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 0
Study 16878328 — intervention group
Group type: EXPERIMENTAL
Intervention: EWS‐ATF1 fusion transcripts detection by real-time PCR analysis on paraffin embedded tissues
Number of subjects: 44
Study 16878328 — intervention group
Group type: EXPERIMENTAL
Intervention: EWS‐ATF1 fusion transcripts detection in probable CCS samples
Number of subjects: 44
Study 16878328 — intervention group
Group type: COMPARATOR
Intervention: EWS‐ATF1 transcripts detection in melanoma samples
Number of subjects: 44
Study 16878328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitotic index and histologic grade
Number of subjects: 44
Study 12420156 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg)
Number of subjects: 40
Study 12420156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10813588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (30 g)
Number of subjects: 42
Study 8665191 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ampicillin prophylaxis for hernia repair
Number of subjects: 850
Study 8665191 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ampicillin prophylaxis for ectopic pregnancy
Number of subjects: 850
Study 8665191 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ampicillin-metronidazole prophylaxis for hysterectomy
Number of subjects: 850
Study 8665191 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ampicillin-metronidazole prophylaxis for caesarean section
Number of subjects: 850
Study 8665191 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ampicillin prophylaxis with or without metronidazole
Number of subjects: 850
Study 8665191 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative penicillin therapy (control)
Number of subjects: 850
Study 1516904 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 6
Study 1516904 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 6
Study 1516904 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine
Number of subjects: 6
Study 6384863 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of daily 0.5 X 10(6) IE fibroblast interferon/kg body weight for 3-5 days
Number of subjects: 0
Study 6384863 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31698177 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 99
Study 28482746 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES+PRO
Number of subjects: 20
Study 28482746 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 20
Study 25211285 — intervention group
Group type: EXPERIMENTAL
Intervention: CCaV at 120 CC per min
Number of subjects: 30
Study 25211285 — intervention group
Group type: EXPERIMENTAL
Intervention: CCaV at 90 CC per min
Number of subjects: 30
Study 25211285 — intervention group
Group type: EXPERIMENTAL
Intervention: 3:1 C:V
Number of subjects: 30
Study 25211285 — intervention group
Group type: COMPARATOR
Intervention: 3:1 C:V and CCaV
Number of subjects: 30
Study 24639698 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxy progesterone caproate (Femolife) injected intramuscularly every week until 36 weeks of gestation
Number of subjects: 106
Study 24639698 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected from 16 until 36 weeks of gestation
Number of subjects: 106
Study 21275923 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-gain restriction program
Number of subjects: 155
Study 18824331 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM-e (800 mg)
Number of subjects: 18
Study 18824331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16952543 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Number of subjects: 87
Study 16952543 — intervention group
Group type: COMPARATOR
Intervention: Conservative bowel management
Number of subjects: 87
Study 15612864 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Mood Scale (positive affect subscale)
Number of subjects: 786
Study 15612864 — intervention group
Group type: COMPARATOR
Intervention: Other questionnaires (not specified)
Number of subjects: 786
Study 11380742 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive geriatrics consultation
Number of subjects: 126
Study 11380742 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 9412912 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily
Number of subjects: 43
Study 9412912 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 43
Study 8387940 — intervention group
Group type: EXPERIMENTAL
Intervention: Men consuming 10 g and 30 g of dietary fibre
Number of subjects: 34
Study 8387940 — intervention group
Group type: EXPERIMENTAL
Intervention: Women consuming 10 g and 30 g of dietary fibre
Number of subjects: 34
Study 3540223 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) verapamil (80 to 120 mg TID)
Number of subjects: 8
Study 3540223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) verapamil (equivalent dose to IR)
Number of subjects: 8
Study 3540223 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) verapamil
Number of subjects: 8
Study 3540223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) verapamil
Number of subjects: 8
Study 3540223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IR and SR verapamil
Number of subjects: 8
Study 30109784 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-Polystyrene Sulfonate (Ca-PS) 3 × 5 g/day for 3 weeks
Number of subjects: 58
Study 30109784 — intervention group
Group type: COMPARATOR
Intervention: Control (blank)
Number of subjects: 58
Study 30109784 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-Polystyrene Sulfonate (Ca-PS)
Number of subjects: 58
Study 28073670 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) simulator training
Number of subjects: 17
Study 28073670 — intervention group
Group type: COMPARATOR
Intervention: Benchtop (BT) simulator training
Number of subjects: 17
Study 26308490 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate, 4%, with 2 showers and a 1-minute pause before rinsing
Number of subjects: 120
Study 26308490 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate, 4%, with 2 showers and a 2-minute pause before rinsing
Number of subjects: 120
Study 26308490 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate, 4%, with 2 showers and no pause before rinsing
Number of subjects: 120